CTI BIOPHARMA CORP (CTIC) Fundamental Analysis & Valuation

NASDAQ:CTIC • US12648L6011

Current stock price

9.09 USD
0 (0%)
At close:
9.09 USD
0 (0%)
After Hours:

This CTIC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. CTIC Profitability Analysis

1.1 Basic Checks

  • In the past year CTIC has reported negative net income.
  • CTIC had a negative operating cash flow in the past year.
CTIC Yearly Net Income VS EBIT VS OCF VS FCFCTIC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

  • CTIC has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CTIC Yearly ROA, ROE, ROICCTIC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 -1K -2K

1.3 Margins

  • Looking at the Gross Margin, with a value of 94.11%, CTIC belongs to the top of the industry, outperforming 95.66% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CTIC has remained more or less at the same level.
  • CTIC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.11%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-1.05%
CTIC Yearly Profit, Operating, Gross MarginsCTIC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. CTIC Health Analysis

2.1 Basic Checks

  • CTIC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CTIC has more shares outstanding
  • Compared to 1 year ago, CTIC has a worse debt to assets ratio.
CTIC Yearly Shares OutstandingCTIC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
CTIC Yearly Total Debt VS Total AssetsCTIC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

2.2 Solvency

  • CTIC has an Altman-Z score of -27.07. This is a bad value and indicates that CTIC is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of CTIC (-27.07) is worse than 88.59% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -27.07
ROIC/WACCN/A
WACC8.93%
CTIC Yearly LT Debt VS Equity VS FCFCTIC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M

2.3 Liquidity

  • CTIC has a Current Ratio of 1.27. This is a normal value and indicates that CTIC is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 1.27, CTIC is doing worse than 84.24% of the companies in the same industry.
  • A Quick Ratio of 1.26 indicates that CTIC should not have too much problems paying its short term obligations.
  • The Quick ratio of CTIC (1.26) is worse than 83.28% of its industry peers.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.26
CTIC Yearly Current Assets VS Current LiabilitesCTIC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. CTIC Growth Analysis

3.1 Past

  • CTIC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 52.46%, which is quite impressive.
  • The Revenue has grown by 3201.48% in the past year. This is a very strong growth!
  • CTIC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.49% yearly.
EPS 1Y (TTM)52.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.97%
Revenue 1Y (TTM)3201.48%
Revenue growth 3Y152.53%
Revenue growth 5Y16.49%
Sales Q2Q%950.81%

3.2 Future

  • Based on estimates for the next years, CTIC will show a very strong growth in Earnings Per Share. The EPS will grow by 31.18% on average per year.
  • The Revenue is expected to grow by 57.28% on average over the next years. This is a very strong growth
EPS Next Y66.63%
EPS Next 2Y57.35%
EPS Next 3Y40.69%
EPS Next 5Y31.18%
Revenue Next Year121.03%
Revenue Next 2Y111.79%
Revenue Next 3Y81.8%
Revenue Next 5Y57.28%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CTIC Yearly Revenue VS EstimatesCTIC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
CTIC Yearly EPS VS EstimatesCTIC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

3

4. CTIC Valuation Analysis

4.1 Price/Earnings Ratio

  • CTIC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 22.47 indicates a rather expensive valuation of CTIC.
  • 95.34% of the companies in the same industry are more expensive than CTIC, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 22.62. CTIC is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 22.47
CTIC Price Earnings VS Forward Price EarningsCTIC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CTIC Per share dataCTIC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

  • CTIC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • CTIC's earnings are expected to grow with 40.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.35%
EPS Next 3Y40.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CTIC Dividend Analysis

5.1 Amount

  • CTIC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CTIC Fundamentals: All Metrics, Ratios and Statistics

CTI BIOPHARMA CORP

NASDAQ:CTIC (6/23/2023, 8:00:00 PM)

After market: 9.09 0 (0%)

9.09

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15
Earnings (Next)08-07
Inst Owners0%
Inst Owner Change0%
Ins Owners16.2%
Ins Owner Change0%
Market Cap1.20B
Revenue(TTM)75.77M
Net Income(TTM)-69.24M
Analysts75.71
Price Target10.7 (17.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend2.39
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.21%
Min EPS beat(2)-41.98%
Max EPS beat(2)15.56%
EPS beat(4)2
Avg EPS beat(4)-2.49%
Min EPS beat(4)-41.98%
Max EPS beat(4)18.65%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-4.51%
Min Revenue beat(2)-12.04%
Max Revenue beat(2)3.03%
Revenue beat(4)3
Avg Revenue beat(4)7.01%
Min Revenue beat(4)-12.04%
Max Revenue beat(4)32.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.9%
PT rev (3m)-6.66%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.62%
EPS NY rev (1m)0%
EPS NY rev (3m)-3674.68%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-11.03%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-20.6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 22.47
P/S 15.82
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)0.4
Fwd EY4.45%
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.62
OCFYN/A
SpS0.57
BVpS-0.19
TBVpS-0.36
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 94.11%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-1.05%
F-Score3
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.27
Quick Ratio 1.26
Altman-Z -27.07
F-Score3
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)52.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.97%
EPS Next Y66.63%
EPS Next 2Y57.35%
EPS Next 3Y40.69%
EPS Next 5Y31.18%
Revenue 1Y (TTM)3201.48%
Revenue growth 3Y152.53%
Revenue growth 5Y16.49%
Sales Q2Q%950.81%
Revenue Next Year121.03%
Revenue Next 2Y111.79%
Revenue Next 3Y81.8%
Revenue Next 5Y57.28%
EBIT growth 1Y52.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-69.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-69.55%
OCF growth 3YN/A
OCF growth 5YN/A

CTI BIOPHARMA CORP / CTIC Fundamental Analysis FAQ

What is the fundamental rating for CTIC stock?

ChartMill assigns a fundamental rating of 3 / 10 to CTIC.


What is the valuation status for CTIC stock?

ChartMill assigns a valuation rating of 3 / 10 to CTI BIOPHARMA CORP (CTIC). This can be considered as Overvalued.


How profitable is CTI BIOPHARMA CORP (CTIC) stock?

CTI BIOPHARMA CORP (CTIC) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for CTIC stock?

The Earnings per Share (EPS) of CTI BIOPHARMA CORP (CTIC) is expected to grow by 66.63% in the next year.